New chemo cocktail targets Hard-to-Treat testicular cancer
NCT ID NCT00183820
First seen Jul 01, 2026 · Last updated Jul 01, 2026
Summary
This study tests a combination of three chemotherapy drugs—gemcitabine, oxaliplatin, and paclitaxel—in people with advanced testicular cancer that has not responded to standard cisplatin-based treatment or has returned after treatment. The goal is to see if this drug combination can shrink tumors or slow the disease. The trial enrolls about 30 adults with refractory germ cell tumors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
gemcitabine, oxaliplatin, and paclitaxel
What this could lead to
If successful, this combination could offer a new treatment option for patients with testicular cancer that has stopped responding to standard chemotherapy.
What could go wrong
This is a small, early-phase study, so the combination may not prove effective enough for wider use. Chemotherapy side effects are expected and can be serious.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TESTICULAR CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Norris Comprehensive Cancer Center
Los Angeles, California, 90033, United States